European Leukemia Trial Registry
Trial: AMLSG 26-16 / AML-ViVA

More Details
Title Phase II Studie mit niedrig-dosiertem Azacitidine, ATRA und Pioglitazon bei älteren Patienten mir refraktärer AML
Scientific Title Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >= 60 years with acute myeloid leukemia who are refractory to standard induction chemotherapy
Short Title AMLSG 26-16 / AML-ViVA
Trialgroup AMLSG Ulm
Type of Trial multicentric, randomized, prospective, open-label, double-group
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 60 years
Status Active
Start of Recruitment 31.05.2017
Leader Thomas, PD Dr. med., Simone
Contactperson

Administrative needs
Montag, Julia
Tel: +49 (0)941 9445537
Email: julia.montag@ukr.de

Study Centre
Weber, Daniela
Tel: +49 (0)731 50056072
Fax: +49 (0)731 50045905
Email: aml.sekretariat@uniklinik-ulm.de

Shortprotocol Shortprotocol
created 08.08.2017 Student Studienregister
changed 23.08.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org